First human trial of Bundibugyo Ebola vaccine begins
Summary
The early-stage trial will enroll 50 healthy adults to assess the vaccine's safety and immune response.
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For Japan, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketJapan
- ImpactMedium (50/100)
- SignalNews